Hematologic Malignancies Program
About Hematologic Malignancies Program
Since lymphoma is a cancer of the immune system, a major scientific goal of the Hematologic Malignancies Program is to use knowledge gained from immunology to understand and treat lymphoid malignancies. This goal is being accomplished by gaining better understanding of the biology underlying lymphoid and myeloid neoplasms and applying this knowledge to improve the diagnosis and treatment of these disorders.
- Discover the Genetic and Cellular Origins of Lymphomas and Leukemias
- Develop Novel Methods of Diagnosis and Biomarker Monitoring of these Diseases
- Develop New Therapies
Hematologic Malignancies Clinical Trials
A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)Stanford is currently accepting patients for this trial.
Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins LymphomaStanford is currently accepting patients for this trial.
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)Stanford is currently accepting patients for this trial.
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaStanford is currently accepting patients for this trial.